CCM
SYRE icon

Cinctive Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Cinctive Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.35M Buy
48,978
+21,548
+79% +$1.57M 0.16% 188
2026
Q1 		$1.38M Sell
27,430
-8,505
-24% -$321K 0.09% 229
2025
Q4 		$1.18M Buy
+35,935
New +$939K 0.06% 265
2025
Q1 		– Sell
-19,567
Closed -$456K – 453
2024
Q4 		$456K Sell
19,567
-41,689
-68% -$1.22M 0.02% 321
2024
Q3 		$1.8M Buy
+61,256
New +$1.71M 0.1% 239

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Cinctive Capital Management's SYRE Position: Q2 2026 in Review

Cinctive Capital Management increased its Spyre Therapeutics (SYRE) stake by 79% in Q2 2026, buying an estimated $1.57M and bringing the position to 48,978 shares worth $4.35M. The position accounts for 0.16% of the portfolio, ranked #188.

Cinctive Capital Management first reported a position in SYRE in Q3 2024 and has held it in 5 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Cinctive Capital Management held 48,978 shares of Spyre Therapeutics worth $4.35M as of Q2 2026.
  • Cinctive Capital Management bought 21,548 Spyre Therapeutics shares in Q2 2026, an estimated $1.57M.
  • Spyre Therapeutics made up 0.16% of Cinctive Capital Management's portfolio in Q2 2026, its #188 holding.
  • Cinctive Capital Management first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.